- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 25 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1083
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more
Clinical trials in Durham, North Carolina
This page shows live ClinicalTrials.gov search results for Durham, North Carolina, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Durham
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Critical Limb Ischemia
- Interventions
- Ixmyelocel-T, Placebo
- Biological · Other
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
- Conditions
- Hemophilia A
- Interventions
- BAX855
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 75 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 18 more
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 14 more
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 92
- States / cities
- La Mesa, California • Long Beach, California • Los Angeles, California + 81 more
- Conditions
- Osteoporosis
- Interventions
- placebo, ALX1-11
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 2,532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip
- Interventions
- Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 100
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Oral Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- Atrial Fibrillation, Arrhythmia
- Interventions
- Left atrial ablation, Rate or Rhythm Control Therapy
- Device · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 2,204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 76
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 66 more
- Conditions
- Preterm Birth
- Interventions
- Not listed
- Lead sponsor
- Sera Prognostics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 5,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Orange, California • San Diego, California + 15 more
- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 141 more